Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET

Company Participants

Yvonne Naughton - Head of Investor Relations and Corporate Communications

Anat Cohen-Dayag - President and Chief Executive Officer

Alberto Sessa - Chief Financial Officer

Henry Adewoye - Chief Medical Officer

Eran Ophir - Chief Scientific Officer

Conference Call Participants

Stephen Willey - Stifel Financial Corp.

Asthika Goonewardene - Truist Securities

Tony Butler - EF Hutton

Operator

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Second Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, today’s call is being recorded. An audio webcast of this call will be made available on the Investors section of Compugen’s website, www.cgen.com.

I would now like to introduce, Yvonne Naughton, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.

Yvonne Naughton

Thank you, operator, and thank you all for joining us on the call today. Joining me for Compugen for the prepared remarks are Dr. Anat Cohen-Dayag, President and Chief Executive Officer; and Alberto Sessa, Chief Financial Officer. Dr. Henry Adewoye, Chief Medical Officer; and Dr. Eran Ophir, Chief Scientific Officer, will join us for the Q&A.

Before we begin, we would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, research and development efforts and their potential outcome, the capabilities of the company’s discovery platform, anticipated progress and plans, results and timelines for its programs, financial and accounting related matters, including projected financial information, as well as statements regarding the company’s future cash position and other results, and the company’s future initiatives.

We wish to caution you that such statements reflect only the company’s current beliefs, expectations and assumptions, but actual results, performance or achievements of the company may differ materially. These statements are subject to known and unknown risks and uncertainties, which could cause the company’s actual results to differ materially from those projected in such forward-looking statements. And we refer you to the SEC filings for more details on these risks, including the company’s most recent annual report on Form 20-F, filed with the SEC on February 28, 2023. The company undertakes no obligation to update projections and forward-looking statements in the future.

And now, I’ll turn the call over to Anat.

Anat Cohen-Dayag

Thank you, Yvonne. Good morning and good afternoon, everyone, and welcome to our second quarter 2023 update. At Compugen, our goal is to transform the treatment of cancer patients who have no effective treatment options by discovering novel drug targets and developing potential first-in-class drugs. On this prompt, we were efficiently executing on our differentiated clinical approach to evaluate the benefit of our chemotherapy-free triple cancer immunotherapy combination of COM701, COM902 and pembrolizumab, blocking free pathways of the DNAM axis PVRIG, TIGIT and PD-1.